Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -40.69% is 165% below its 4-year average of -15.37%, around the middle of its 4-year range (-76.86%–0.00%).
5.88% below its 12-month average of -38.43%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -8.28%.
RETURN ON ASSETS (ROA)
-40.69%
RETURN ON ASSETS (ROA) AVG TTM
-38.43%
RETURN ON ASSETS (ROA) AVG 3Y
-19.21%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-5.88%
CURRENT VS 3Y AVG
-111.76%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.75%
median of 749 covered companies
CURRENT VS SECTOR MEDIAN
-32.33%
vs the sector median at left
Filana Therapeutics, Inc.
Market Cap
$40.42M
Return on Assets (ROA)
-40.69%
TTM Avg
-38.43%
3Y Avg
-19.21%
5Y Avg
N/A
Market Cap
$40.28M
Return on Assets (ROA)
-53.81%
TTM Avg
-31.90%
3Y Avg
-23.26%
5Y Avg
-21.62%
Market Cap
$39.96M
Return on Assets (ROA)
11.01%
TTM Avg
4.71%
3Y Avg
-17.75%
5Y Avg
-20.00%
Market Cap
$39.08M
Return on Assets (ROA)
-13.65%
TTM Avg
-40.30%
3Y Avg
-22.41%
5Y Avg
-15.81%
Market Cap
$41.92M
Return on Assets (ROA)
-5.70%
TTM Avg
-13.47%
3Y Avg
-29.01%
5Y Avg
-32.57%
Market Cap
$38.35M
Return on Assets (ROA)
-26.45%
TTM Avg
-127.88%
3Y Avg
-142.31%
5Y Avg
-121.77%
Market Cap
$42.97M
Return on Assets (ROA)
-57.95%
TTM Avg
4.78%
3Y Avg
-64.05%
5Y Avg
-66.64%
Market Cap
$37.33M
Return on Assets (ROA)
-110.85%
TTM Avg
-107.44%
3Y Avg
-115.17%
5Y Avg
-101.88%
Market Cap
$43.96M
Return on Assets (ROA)
-128.10%
TTM Avg
-35.87%
3Y Avg
-35.25%
5Y Avg
-29.40%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Filana Therapeutics, Inc. (FLNA) | $40.42M | -40.69% | -38.43% | -19.21% | N/A |
| Metagenomi, Inc. Common Stock (MGX)vs › | $40.28M | -53.81% | -31.90% | -23.26% | -21.62% |
| Nephros, Inc. (NEPH)vs › | $39.96M | 11.01% | 4.71% | -17.75% | -20.00% |
| Harvard Bioscience, Inc. (HBIO)vs › | $39.08M | -13.65% | -40.30% | -22.41% | -15.81% |
| Precipio, Inc. (PRPO)vs › | $41.92M | -5.70% | -13.47% | -29.01% | -32.57% |
| Incannex Healthcare Limited (IXHL)vs › | $38.35M | -26.45% | -127.88% | -142.31% | -121.77% |
| BioStem Technologies, Inc. (BSEM)vs › | $42.97M | -57.95% | 4.78% | -64.05% | -66.64% |
| Edesa Biotech, Inc. (EDSA)vs › | $37.33M | -110.85% | -107.44% | -115.17% | -101.88% |
| Nano-X Imaging Ltd. (NNOX)vs › | $43.96M | -128.10% | -35.87% | -35.25% | -29.40% |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.61M | -120.78% | -168.59% | -147.82% | -131.31% |
ROA
-40.7%
ROE
-66.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -76.86% |
| 2024-12-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2021-12-31 | 0.00% |
